Subscribe to news

Press Center

27.01.2014
In early January 2014, the magazine Der Aktionaer published an analytical report which indicated a potential upside of 150% for the German cord blood stem cell bank Vita 34, indicating a target price of €10 per share.
14.01.2014
OJSC HSCI, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announces a change in the company’s shareholding structure.
04.12.2013
OJSC HSCI, one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its ordinary shares to be included in the Broad Market Index and the Second-Tier Index of the Moscow Exchange.
15.11.2013
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its unaudited unconsolidated results for the first nine months of 2013 in accordance with the Russian Accounting Standards (RAS)
30.08.2013
OJSC HSCI – The Human Stem Cells Institute (“HSCI”, MICEX: ISKJ), one of Russia’s leading biotech companies specializing in cell-based, gene and post-genome technologies, today announced its unaudited consolidated interim results for the first half of 2013 (6 months ended June 30, 2013) under International Financial Reporting Standards (IFRS)
16.08.2013
More than 200 million people worldwide suffer from Peripheral Artery Disease (PAD) according to data published in the August issue of the The Lancet.
16.08.2013
The Human Stem Cells Institute, today announced its unaudited unconsolidated results for the first half of 2013 in accordance with the Russian Accounting Standards (RAS)
20.06.2013
OJSC HSCI, today announced the results of the Annual General Shareholders’ Meeting (AGM) held on June 20, 2013, in Moscow.
20.05.2013
OJSC HSCI, today announced the decision of the Company’s Board of Directors on the agenda of the Annual General Shareholders’ Meeting upon the results of 2012.
16.05.2013
The Human Stem Cells Institute, one of Russia’s leading biotech companies, today announced its results for the first quarter of 2013 in accordance with the Russian Accounting Standards (RAS)